Establishment of a human hepatoma multidrug resistant cell line in vitro.
OBJECTIVE
To establish a multidrug-resistant hepatoma cell line (SK-Hep-1), and to investigate its biological characteristics.


METHODS
A highly invasive SK-Hep-1 cell line of human hepatocellular carcinoma, also known as malignant hepatoma was incubated with a high concentration of cisplatin (CDDP) to establish a CDDP-resistant cell subline (SK-Hep-1/CDDP). The 50% inhibitory dose (IC(50)) values and the resistance indexes [(IC(50) SK-Hep-1/CDDP)/(IC(50) SK-Hep-1)] for other chemotherapeutic agents and the growth curve of cells were all evaluated using cell counting kit-8 assays. The distribution of the cell cycles were detected by flow cytometry. Expression of acquired multidrug resistance P-glycoprotein (MDR1, ABCB1) and multidrug resistance-associated protein 1 (MRP1, ABCC1) was compared with that in parent cells by Western blotting and immunofluorescence combined with laser scanning confocal microscopy.


RESULTS
The SK-Hep-1/CDDP cells (IC(50) = 70.61 +/- 1.06 microg/mL) was 13.76 times more resistant to CDDP than the SK-Hep-1 cells (IC(50) = 5.13 +/- 0.09 microg/mL), and CDDP-resistant cells also demonstrated cross-resistance to many anti-tumor agents such as doxorubicin, 5-fluorouracil and vincristine. Similar morphologies were determined in both SK-Hep-1 and SK-Hep-1/CDDP groups. The cell cycle distribution of the SK-Hep-1/CDDP cell line exhibited a significantly increased percentage of cells in S (42.2% +/- 2.65% vs 27.91% +/- 2.16%, P < 0.01) and G2/M (20.67% +/- 5.69% vs 12.14% +/- 3.36%, P < 0.01) phases in comparison with SK-Hep-1 cells, while the percentage of cells in the G0/G1 phase decreased (37.5% +/- 5.05% vs 59.83% +/- 3.28%, P < 0.01). The levels of MDR1 and MRP1 were overexpressed in the SK-Hep-1/CDDP cells exhibiting the MDR phenotype.


CONCLUSIONS
Multiple drug resistance of multiple drugs in the human hepatoma cell line SK-Hep-1/CDDP was closely related to the overexpression of MDR1 and MRP1.
Zhou
Yuan
Y
Department of Gastroenterology, Xinqiao Hospital, Third Military Medical University, Chongqing 400037, China.
Ling
Xian-Long
XL
Li
Shi-Wei
SW
Li
Xin-Qiang
XQ
Yan
Bin
B
D018435:ATP Binding Cassette Transporter, Subfamily B; D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000378:metabolism; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D018929:Cell Culture Techniques; D045744:Cell Line, Tumor; D002945:Cisplatin / Q000494:pharmacology; D018432:Drug Resistance, Multiple; D019008:Drug Resistance, Neoplasm; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D027425:ATP-Binding Cassette, Sub-Family C Proteins / Q000378:metabolism
D018435:ATP Binding Cassette Transporter, Subfamily B; D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D002945:Cisplatin; D027425:ATP-Binding Cassette, Sub-Family C Proteins; C513055:ABCB1 protein, human; C421109:multidrug resistance-associated protein 1
Nat Med. 2006 Apr;12(4):410-6
16532004
Oncologist. 2007 Aug;12(8):927-41
17766652
Cancer Res. 2006 Mar 1;66(5):2673-82
16510587
J Hepatol. 2004 Feb;40(2):298-304
14739102
Curr Med Chem. 2006;13(16):1859-76
16842198
Liver Int. 2005 Apr;25(2):367-79
15780063
Br J Cancer. 1986 Apr;53(4):529-37
3011054
Int J Cancer. 2001 Nov;94(4):492-9
11745434
Int J Cancer. 2001 Oct 15;94(2):153-6
11668491
Liver Int. 2008 Dec;28(10):1370-80
19055643
Lancet Oncol. 2002 Oct;3(10):593-603
12372721
Anticancer Drugs. 2007 Aug;18(7):749-54
17581296
Cancer Chemother Pharmacol. 2002 Jun;49(6):438-44
12107547